Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals

Clinical and Vaccine Immunology

Volumn 21, Issue 3, 2014, Pages 443-452

  Anderson, Jenna ^a   Bréard, Emmanuel ^b   Bengtsson, Karin Lövgren ^c   Grönvik, Kjell Olov ^d,e   Zientara, Stéphan ^b   Valarcher, Jean Francois ^a,d   Hägglund, Sara ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c NOVAVAX INC   (United States)

^d NATIONAL VETERINARY INSTITUTE   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLUETONGUE VIRUS PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; ISCOM MATRIX ADJUVANT; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; RECOMBINANT NONSTRUCTURAL PROTEIN 1; RECOMBINANT NONSTRUCTURAL PROTEIN 2; RECOMBINANT NONSTRUCTURAL PROTEIN 3; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN VP2; RECOMBINANT PROTEIN VP5; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BLUETONGUE ORBIVIRUS; CATTLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG PURIFICATION; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACULOVIRIDAE; BLUETONGUE VIRUS; CATTLE; CELL PROLIFERATION; CHOLESTEROL; DRUG COMBINATIONS; ESCHERICHIA COLI; GENE EXPRESSION; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTES; MICE; PHOSPHOLIPIDS; PROTEIN STABILITY; SAPONINS; VACCINATION; VACCINES, MARKER; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84896785038     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00776-13     Document Type: Article

References (64)

1. Metz SW, Pijlman GP. 2011. Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. J. Invertebr. Pathol. 107(Suppl):S16-S30. http://dx.doi.org/10.1016/j.jip.2011.05.002.
2. Roy P, Boyce M, Noad R. 2009. Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 7:120-128. http://dx.doi.org/10.1038/nrmicro2052.
3. Zientara S, Sánchez-Vizcaíno JM. 2013. Control of bluetongue in Europe. Vet. Microbiol. 165:33-37. http://dx.doi.org/10.1016/j. vetmic.2013.01.010.
4. Zanella G, Martinelle L, Guyot H, Mauroy A, De Clercq K, Saegerman C. 2013. Clinical pattern characterization of cattle naturally infected by BTV-8. Transbound. Emerg. Dis. 60:231-237. http://dx.doi.org/10.1111/j.1865-1682.2012. 01334.x.
5. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu H-H, Anthony SJ, Elliott H, Mertens PPC, Mellor PS. 2010. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 28:1397-1403. http://dx.doi.org/10.1016/j. vaccine.2009.10.107.
6. Veronesi E, Hamblin C, Mellor PS. 2005. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23:5509-5516. http://dx.doi.org/10.1016/j. vaccine.2005.07.039. (Pubitemid 41608599)
7. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PPC. 2008. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res. 137:56-63. http://dx.doi.org/10.1016/j. virusres.2008.05.016.
8. Maan S, Maan NS, van Rijn PA, van Gennip RGP, Sanders A, Wright IM, Batten C, Hoffmann B, Eschbaumer M, Oura CAL, Potgieter AC, Nomikou K, Mertens PPC. 2010. Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains. PLoS One 5:e10323. http://dx.doi.org/10.1371/journal.pone.0010323.
9. Savini G, Lorusso A, Paladini C, Migliaccio P, Di Gennaro A, Di Provvido A, Scacchia M, Monaco F. 2014. Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy. Transbound. Emerg. Dis. 61:69-74. http://dx.doi.org/10.1111/tbed. 12004.
10. Savini G, MacLachlan NJ, Sanchez-Vizcaino J-M, Zientara S. 2008. Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 31:101-120. http://dx.doi.org/10.1016/j.cimid.2007.07.006. (Pubitemid 351315116)
11. Paton DJ, Taylor G. 2011. Developing vaccines against foot-and-mouth disease and some other exotic viral diseases of livestock. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366:2774-2781. http://dx.doi.org/10.1098/rstb.2011.0107.
12. Noad R, Roy P. 2009. Bluetongue vaccines. Vaccine 27(Suppl 4):D86-D89. http://dx.doi.org/10.1016/j.vaccine.2009.08.037.
13. Wade-Evans AM, Romero CH, Mellor P, Takamatsu H, Anderson J, Thevasagayam J, Fleming MJ, Mertens PPC, Black DN. 1996. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology. 220:227-231. http://dx.doi.org/10.1006/viro.1996. 0306.
14. Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. 2007. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25:6774-6783. http://dx.doi.org/10.1016/j.vaccine.2007.06.052. (Pubitemid 47337132)
15. Boone JD, Balasuriya UB, Karaca K, Audonnet J-C, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, MacLachlan NJ. 2007. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25:672-678. http://dx.doi.org/10.1016/j.vaccine.2006.08.025. (Pubitemid 44873152)
16. Jones LD, Williams T, Bishop D, Roy P. 1997. Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection. Clin. Diagn. Lab. Immunol. 4:297-301. (Pubitemid 27239688)
17. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. 1990. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64:1998-2003. (Pubitemid 20148441)
18. Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos O, Roy P. 2012. Protective efficacy of bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 30:2131-2139. http://dx.doi.org/10.1016/j.vaccine.2012.01.042.
19. Riffault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, Soulestin M, Castagné N, Bernard J, Bernardet P, Dubosclard V, Bernex F, Petit-Camurdan A, Deville S, Schwartz-Cornil I, Eléouët J-F. 2010. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28:3722-3734. http://dx.doi.org/10.1016/j.vaccine.2010. 03.008.
20. Shin M-K, Yoo HS. 2013. Animal vaccines based on orally presented yeast recombinants. Vaccine 31:4287-4292. http://dx.doi.org/10.1016/j.vaccine.2013.07. 029.
21. Guerrero-Andrade O, Loza-Rubio E, Olivera-Flores T, Fehérvá ri-Bone T, Gómez-Lim MA. 2006. Expression of the Newcastle disease virus fusion protein in transgenic maize and immunological studies. Transgenic Res. 15:455-463. http://dx.doi.org/10.1007/s11248-006-0017-0. (Pubitemid 44215634)
22. Martínez-Torrecuadrada JL, Díaz-Laviada M, Roy P, Sánchez C, Vela C, Sánchez-Vizcaíno JM, Casal JI. 1996. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. J. Gen. Virol. 77:1211-1221. http://dx.doi.org/10.1099/0022-1317-77-6-1211. (Pubitemid 26185502)
23. Young CL, Britton ZT, Robinson AS. 2012. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnol. J. 7:620-634. http://dx.doi.org/10.1002/biot. 201100155.
24. International Committee on Taxonomy of Viruses. 2011. Virus taxonomy: 9th report of the International Committee on Taxonomy of Viruses. Elsevier, Oxford, United Kingdom.
25. Calvo-Pinilla E, Navasa N, Anguita J, Ortego J. 2012. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7:e34735. http://dx.doi.org/10.1371/journal.pone. 0034735.
26. Jeggo MH, Gumm ID, Taylor WP. 1983. Clinical and serological response of sheep to serial challenge with different bluetongue virus types. Res. Vet. Sci. 34:205-211. (Pubitemid 13134634)
27. Umeshappa CS, Singh KP, Pandey AB, Singh RP, Nanjundappa RH. 2010. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep. Vaccine 28:2522-2531. http://dx.doi.org/10.1016/j.vaccine.2010.01.039.
28. Huismans H, Erasmus BJ. 1981. Identification of the serotype-specific and group-specific antigens of bluetongue virus. Onderstepoort J. Vet. Res. 48:51-58.
29. Inumaru S, Roy P. 1987. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. Virology 157:472-479. http://dx.doi.org/10.1016/0042-6822(87) 90289-3. (Pubitemid 17047702)
30. Wang L-F, Du Plessis DH, White JR, Hyatt AD, Eaton BT. 1995. Use of a gene-targeted phage displayrandomepitope library tomapanantigenic determinant on the bluetongue virus outer capsid protein VP5. J. Immunol. Methods 178:1-12. http://dx.doi.org/10.1016/0022-1759(94)00235-O.
31. Wang W-S, Sun E, Liu N-H, Yang T, Xu Q-Y, Qin Y-L, Zhao J, Feng Y-F, Li J-P, Wei P, Zhang C-Y, Wu D. 2013. Identification of three novel linear B-cell epitopes on the VP5 protein of BTV16. Vet. Microbiol. 162: 631-642. http://dx.doi.org/10.1016/j.vetmic.2012.11.042.
32. Mertens PPC, Ross-Smith N, Diprose J, Attoui H. 2009. The structure of bluetongue virus core and proteins, p 101-133. In Bluetongue. Academic Press, New York, NY.
33. Gumm ID, Newman JF. 1982. The preparation of purified bluetongue virus group antigen for use as a diagnostic reagent. Arch. Virol. 72:83-93. http://dx.doi.org/10.1007/BF01314453. (Pubitemid 12063519)
34. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu H-H, Mertens PPC, Castillo-Olivares J. 2013. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 8:e60574. http://dx.doi.org/10.1371/journal.pone.0060574.
35. Inumaru S, Ghiasi H, Roy P. 1987. Expression of bluetongue virus group-specific antigen VP3 in insect cells by a baculovirus vector: its use for the detection of bluetongue virus antibodies. J. Gen. Virol. 68(Part 6):1627-1635. http://dx.doi.org/10.1099/0022-1317-68-6-1627. (Pubitemid 17115724)
36. Lobato ZIP, Coupar BEH, Gray CP, Lunt R, Andrew ME. 1997. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 59: 293-309. http://dx.doi.org/10.1016/S0165-2427(97)00084-6. (Pubitemid 28072828)
37. Janardhana V, Andrew ME, Lobato ZI, Coupar BE. 1999. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res. Vet. Sci. 67: 213-221. http://dx.doi.org/10.1053/rvsc.1999.0306. (Pubitemid 129646891)
38. Roy P, Bishop DH, LeBlois H, Erasmus BJ. 1994. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence forhomologousandpartial heterologous protection. Vaccine 12:805-811. http://dx.doi.org/10.1016/0264-410X(94)90289-5. (Pubitemid 24190561)
39. Jones LD, Chuma T, Hails R, Williams T, Roy P. 1996. The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. J. Gen. Virol. 77(Part 5):997-1003. http://dx.doi.org/10.1099/ 0022-1317-77-5-997. (Pubitemid 26142334)
40. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, Coupar B. 1995. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet. Immunol. Immunopathol. 47:311-322. http://dx.doi.org/10.1016/0165- 2427(94)05410-T.
41. Anderson J, Mertens PP, Herniman KA. 1993. A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1. J. Virol. Methods 43:167-175. http://dx.doi.org/10.1016/0166-0934(93)90074-2.
42. Barros SC, Cruz B, Luís TM, Ramos F, Fagulha T, Duarte M, Henriques M, Fevereiro M. 2009. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus. Vet. Microbiol. 137:252-259. http://dx.doi.org/10.1016/j.vetmic.2009.01.033.
43. Mecham JO, Dean VC, Jochim MM. 1986. Correlation of serotype specificity and protein structure of the five U.S. serotypes of bluetongue virus. J. Gen. Virol. 67(Part 12):2617-2624. http://dx.doi.org/10.1099/0022-1317-67-12-2617. (Pubitemid 17197592)
44. Jeggo MH, Wardley RC. 1982. Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types. Immunology 45:629-635. (Pubitemid 12132270)
45. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671-675. http://dx.doi.org/10.1038/ nmeth.2089.
46. R Development Core Team. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
47. Anderson J, Hägglund S, Bréard E, Comtet L, Lövgren Bengtsson K, Pringle J, Zientara S, Valarcher J-F. 2013. Evaluation of the immunogenicity of an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. Clin. Vaccine Immunol. 20:1115-1122. http://dx.doi.org/10. 1128/CVI.00229-13.
48. Maan S, Maan NS, Ross-Smith N, Batten CA, Shaw AE, Anthony SJ, Samuel AR, Darpel KE, Veronesi E, Oura CAL, Singh KP, Nomikou K, Potgieter AC, Attoui H, van Rooij E, van Rijn P, De Clercq K, Vandenbussche F, Zientara S, Bréard E, Sailleau C, Beer M, Hoffman B, Mellor PS, Mertens PPC. 2008. Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains. Virology 377:308-318. http://dx.doi.org/10.1016/j. virol.2008.04.028. (Pubitemid 351836080)
49. Mecham JO, Wilson WC. 2004. Antigen capture competitive enzyme-linked immunosorbentassays using baculovirus-expressed antigens for diagnosis of bluetongue virus and epizootic hemorrhagic disease virus. J. Clin.Microbiol. 42:518-523. http://dx.doi.org/10.1128/JCM.42.2.518-523.2004. (Pubitemid 38222622)
50. Kelly EP, Greene JJ, King AD, Innis BL. 2000. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18:2549-2559. http://dx.doi.org/10.1016/S0264-410X(00)00032-3. (Pubitemid 30207040)
51. van Rijn PA, van de Water SGP, van Gennip HGP. 2013. Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: a genetic DIVA approach. Vaccine 31:5005-5008. http://dx.doi.org/10. 1016/j.vaccine.2013.08.089.
52. Celma CC, Boyce M, van Rijn PA, Eschbaumer M, Wernike K, Hoffmann B, Beer M, Haegeman A, Clercq KD, Roy P. 2013. Rapid generation of replication- deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. J. Virol. 87: 9856-9864. http://dx.doi.org/10.1128/JVI.01514-13.
53. Kost TA, Condreay JP, Jarvis DL. 2005. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 23:567-575. http://dx.doi.org/10.1038/nbt1095. (Pubitemid 41724895)
54. Nason EL, Rothagel R, Mukherjee SK, Kar AK, Forzan M, Prasad BVV, Roy P. 2004. Interactions between the inner and outer capsids of blue-tongue virus. J. Virol. 78:8059-8067. http://dx.doi.org/10.1128/JVI.78.15.8059-8067.2004. (Pubitemid 38944290)
55. Hassan SH, Wirblich C, Forzan M, Roy P. 2001. Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilization. J. Virol. 75:8356-8367. http://dx.doi.org/10.1128/JVI.75.18. 8356-8367.2001. (Pubitemid 32768940)
56. Hassan SS, Roy P. 1999. Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. J. Virol. 73:9832-9842.
57. Morein B, Bengtsson KL. 1999. Immunomodulation by iscoms, immune stimulating complexes. Methods 19:94-102. http://dx.doi.org/10.1006/meth.1999. 0833. (Pubitemid 29497758)
58. Morein B, Hu K-F, Abusugra I. 2004. Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Deliv. Rev. 56:1367-1382. http://dx.doi.org/10.1016/j.addr.2004.02.004. (Pubitemid 38748821)
59. Lövgren Bengtsson K, Morein B, Osterhaus AD. 2011. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10:401-403. http://dx.doi.org/10.1586/erv.11. 25.
60. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. 2012. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J. Med. Microbiol. 61:935-943. http://dx.doi.org/ 10.1099/jmm.0.040857-0.
61. Hägglund S, Hu K, Vargmar K, Poré L, Olofson A-S, Blodörn K, Anderson J, Ahooghalandari P, Pringle J, Taylor G, Valarcher J-F. 2011. Bovine respiratory syncytial virus ISCOMs - immunity, protection and safety in young conventional calves. Vaccine 29:8719-8730. http://dx.doi.org/10. 1016/j.vaccine.2011.07.146.
62. Paillot R, Prowse L. 2012. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse. Vet. Immunol. Immunopathol. 145:516-521. http://dx.doi.org/10.1016/j.vetimm.2011.11.019.
63. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. 2012. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206:158-166. http://dx.doi.org/10.1093/infdis/ jis330.
64. Adkison MA, Stott JL, Osburn BI. 1988. Temporal development of bluetongue virus protein-specific antibody in sheep following natural infection. Vet. Microbiol. 16:231-241. http://dx.doi.org/10.1016/0378-1135(88)90027-2.